Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 03.04.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensat |
| 23.02.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensat |
Stammdaten
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.
Unternehmen & Branche
| Name | Ayala Pharmaceuticals, Inc. |
|---|---|
| Ticker | ADXS |
| CIK | 0001100397 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 25,7 Mio. USD |
| Beta | -4,03 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2023-12-31 | 10-K | 13,000 | -48,072,000 | -7.99 | 16,579,000 | -24,417,000 |
| 2023-09-30 | 10-Q | 13,000 | -7,339,000 | -1.53 | 6,981,000 | -6,241,000 |
| 2023-06-30 | 10-Q | 9,000 | -8,699,000 | -1.82 | 12,151,000 | 1,009,000 |
| 2023-03-31 | 10-Q | 4,000 | -7,361,000 | 20,995,000 | 9,675,000 | |
| 2022-12-31 | 10-K | 692,000 | -38,013,000 | -13.13 | 7,769,000 | -1,099,000 |
| 2022-10-31 | 10-K | 250,000 | -14,359,000 | 25,930,000 | 23,627,000 | |
| 2022-09-30 | 10-Q | 91,000 | -10,185,000 | -3.51 | 8,338,000 | |
| 2022-07-31 | 10-Q | 250,000 | -6,963,000 | 30,101,000 | 28,195,000 | |
| 2022-06-30 | 10-Q | 38,000 | -8,108,000 | -2.83 | 17,539,000 | |
| 2022-04-30 | 10-Q | 250,000 | -2,440,000 | 37,518,000 | 35,151,000 | |
| 2022-03-31 | 10-Q | 458,000 | -9,953,000 | 24,892,000 | ||
| 2022-01-31 | 10-Q | -365,000 | 46,498,000 | 38,549,000 | ||
| 2021-10-31 | 10-K | 3,240,000 | -17,862,000 | 46,780,000 | 38,888,000 | |
| 2021-07-31 | 10-Q | 250,000 | -3,334,000 | 51,022,000 | 44,277,000 | |
| 2021-04-30 | 10-Q | 1,375,000 | -5,107,000 | 55,771,000 | 47,551,000 | |
| 2021-01-31 | 10-Q | 1,615,000 | -3,977,000 | 45,947,000 | 37,575,000 | |
| 2020-10-31 | 10-K | 253,000 | -26,469,000 | 38,526,000 | 30,180,000 | |
| 2020-07-31 | 10-Q | 253,000 | -5,829,000 | 40,019,000 | 31,466,000 | |
| 2020-04-30 | 10-Q | 250,000 | -6,323,000 | -0.10 | 45,210,000 | 35,437,000 |
| 2020-01-31 | 10-Q | 3,000 | -7,857,000 | 51,348,000 | 41,548,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
Keine Insider-Käufe/Verkäufe in den letzten 12 Monaten.
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.